Type 2 Diabetes | Disease Landscape & Forecast | G7 | 2021

The type 2 diabetes (T2D) therapy market will expand over the first half of the 2020-2030 forecast period. This increase will partly be fueled by a rich pipeline of novel agents, including emerging therapies that are expected to demonstrate superior dosing and efficacy over current therapies. Notable growth is expected for the sodium glucose co-transporter-2 (SGLT-2) inhibitors and the glucagon-like peptide-1 (GLP-1) receptor agonists owing to their efficacy in glycemic control and weight loss and demonstration of cardiovascular (CV) benefits. However, increasing genericization will build market access pressures on the uptake of branded therapies, most notably from the arrival of generic DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 receptor agonists.


  • How will the release of Novo Nordisk’s Rybelsus, a novel oral GLP-1 receptor, affect the prescribing of injectable GLP-1 receptor agonists such as Eli Lilly’s Trulicity and Novo Nordisk’s Ozempic and Victoza?
  • Will label expansions of the SGLT-2 inhibitors—AstraZeneca’s Farxiga and Johnson & Johnson’s Invokana—affect the uptake of Boehringer Ingelheim / Eli Lilly’s Jardiance?
  • What do key opinion leaders think about emerging therapies such as Eli Lilly’s tirzepatide, Novo Nordisk’s insulin icodec, Oramed Pharmaceuticals’ ORMD-0801, and Poxel imeglimin?


Geographies: United States, EU5, Japan.

Primary research: 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: prevalence of T2D by country with population-specific diagnosed and drug-treatment rates.

Forecast: 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2030, segmented by brands / generics.

Emerging therapies: Phase III/PR: 8 drugs; coverage of select preclinical, Phase I, and Phase II products.


Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Login to access report